Cigna's 27% Revenue Increase in 2024 and the Outlook on 2025
January 30th 2025The Cigna Group reported today their total revenue of $247.1 billion for 2024, compared with $195.3 billion in 2023. This growth highlights the company’s strong financial results, supported by the success of Evernorth Health Services, new client acquisitions and growth in the specialty drug space.
Read More
FDA Approves Spravato Nasal Spray as a Standalone Treatment for Major Depressive Disorder
January 21st 2025One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.
Read More
Combined Oral and Phototherapy Treatments Show Promise in Treating Severe Vitiligo
January 21st 2025In a phase 2 clinical trial, researchers examined baricitinib and NB-UVB in adults with severe vitiligo in the dermatology departments at 4 hospitals in France between July 2021 and April 2023.
Read More
Study Estimates 5 Million People Could Benefit from Magic Mushrooms for Depression Treatment
December 5th 2024Psilocybin-assisted therapy, which involves using the active ingredient from "magic mushrooms," could benefit roughly 5 million people currently receiving treatment for major depressive disorder and treatment-resistant depression if the FDA approves it.
Read More
New Study to Explore Impact of Type 1 Diabetes on Children's Brain Development
December 2nd 2024A new nationwide study led by the Keck School of Medicine of USC aims to examine how type 1 diabetes impacts children's brain development and cognitive function, focusing on diverse participants and paving the way for early interventions and better diabetes management.
Read More